SomaLogic (NASDAQ:SLGC) vs. Bioqual (OTCMKTS:BIOQ) Head to Head Contrast

SomaLogic (NASDAQ:SLGCGet Rating) and Bioqual (OTCMKTS:BIOQGet Rating) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

44.6% of SomaLogic shares are held by institutional investors. 39.2% of Bioqual shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares SomaLogic and Bioqual’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SomaLogic N/A -30.93% -19.50%
Bioqual 9.38% N/A N/A

Valuation and Earnings

This table compares SomaLogic and Bioqual’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SomaLogic $81.63 million 15.35 -$87.55 million N/A N/A
Bioqual $57.68 million 1.40 $6.33 million $6.28 14.33

Bioqual has lower revenue, but higher earnings than SomaLogic.

Analyst Recommendations

This is a breakdown of current recommendations for SomaLogic and Bioqual, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SomaLogic 0 0 3 0 3.00
Bioqual 0 0 0 0 N/A

SomaLogic presently has a consensus price target of $15.33, suggesting a potential upside of 122.87%. Given SomaLogic’s higher probable upside, research analysts clearly believe SomaLogic is more favorable than Bioqual.

SomaLogic Company Profile (Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Bioqual Company Profile (Get Rating)

Bioqual, Inc. engages in the provision and development of medical research and consulting services to commercial clients and government laboratories. It focuses on animal models of human diseases including COVID-19, Zika, AIDS, Influenza, RSV, Malaria, and other infectious disease areas. The company was founded by John C. Landon on June 1, 1981 and is headquartered in Rockville, MD.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.